MannKind Corporation

381 articles about MannKind Corporation

• MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics

  11/19/2020

  MannKind Corporation announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil.

• MannKind Corporation Reports 2020 Third Quarter Financial Results

  11/4/2020

  MannKind Corporation reported financial results for the quarter and nine months ended September 30, 2020.

• MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020

  10/29/2020

  MannKind Corporation will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM on Wednesday, November 4, 2020.

• MannKind Corporation Participating at Upcoming Conferences - Sep 08, 2020

  9/8/2020

  MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced that it will be participating at upcoming conferences.

• MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020

  8/7/2020

  MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 2:00 pm.

• MannKind Corporation Reports 2020 Second Quarter Financial ResultsConference Call to Begin Today at 5:00 PM ET

  8/5/2020

  MannKind Corporation reported financial results for the quarter and six months ended June 30, 2020.

• Alejandro Galindo Joins MannKind as Chief Commercial Officer

  7/20/2020

  MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020, Alejandro Galindo, M.B.A, M.S., will be leading MannKind’s commercial operations as Chief Commercial Officer

• MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference

  6/17/2020

  MannKind Corporation announced that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET.

• Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM

  6/13/2020

  MannKind Corporation announced that data from a new clinical study of Afrezza® Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sessions during the ePoster session on Saturday, June 13, 2020.

• MannKind Corporation Reports 2020 First Quarter Financial Results

  5/6/2020

  MannKind Corporation reported financial results for the quarter ended March 31, 2020.

• MannKind Receives Forgivable Loan under the Paycheck Protection Program

  4/15/2020

  Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented

• MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic

  3/17/2020

  MannKind Corporation announced that it is adjusting research and development resources that were reserved for its pipeline of investigational products for treating serious lung diseases, with the goal of prioritizing work on new compounds that may have the potential to address the morbidity and mortality associated with respiratory viral infections, such as COVID-19.

• MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial ResultsConference Call to Begin Today at 9:00 AM ET

  2/25/2020

  MannKind Corporation reported financial results for the fourth quarter and full year ended December 31, 2019.

• MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference

  2/24/2020

  MannKind Corporation announced that it will be featured as a presenting company at the 9th Annual SVB Leerink Global Healthcare Conference on Thursday, February 27, 2020 at 9:30 am at the Lotte New York Palace Hotel in New York, NY.

• MannKind Corporation to Hold 2019 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2020

  2/18/2020

  MannKind Corporation will release its 2019 fourth quarter and full year financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM on Tuesday, February 25, 2020.

• MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference

  11/29/2019

  MannKind Corporation announced that it will be featured as a presenting company at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 3:30 p.m. at the Lotte New York Palace in New York City.

• MannKind Appoints Tony Hooper to Its Board of Directors

  11/21/2019

  MannKind Corporation announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020.

• MannKind Corporation Reports 2019 Third Quarter Preliminary Financial ResultsConference Call to Begin Today at 9:00 AM ET

  11/6/2019

  MannKind Corporation (NASDAQ:MNKD) today reported preliminary financial results for the quarter and nine months ended September 30, 2019.

• MannKind Corporation to Hold 2019 Third Quarter Financial Results Conference Call on November 6, 2019

  10/30/2019

  WESTLAKE VILLAGE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2019 third quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM (Eastern Time) on Wednesday, November 6, 2019. Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.  To participate in the live call by telep

• United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement

  10/16/2018

  United Therapeutics Corporation and MannKind Corporation today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension.